Tests acetazolamide with usual drugs in heart failure patients with fluid buildup
Studies whether adding acetazolamide to furosemide and SGLT2 inhibitors helps remove extra salt and water.
Plain-language title generated from the registry record
Registry title: Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)
Key facts
- Where
- Madrid, SpainSee the site
Where in Spain
- Julia González GonzálezMadrid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Puerta de Hierro University Hospital
- Trial code
- NCT06285760
- Record updated
- 29 December 2025
- Original description
The goal of this observational study is to assess the natriuretic effect of intravenous acetazolamide in patients admitted with heart failure and persistent congestion despite treatment with intravenous furosemide and sodium-glucose cotransporter type 2 (iSGLT2) inhibitors.Read full original descriptionShow less
SANDI STUDY: Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure.
The goal of this observational study is to assess the natriuretic effect of intravenous acetazolamide in patients admitted with heart failure and persistent congestion despite treatment with intravenous furosemide and sodium-glucose cotransporter type 2 (iSGLT2) inhibitors.
The main question it aims to answer is whether there is a difference in natriuresis 24 hours after acetazolamide association to medical treatment recommended by the guidelines (furosemide and ISGLT2).
Inclusion: Patients admitted for acute heart failure and ≥ 1 clinical sign of volume overload (edema, ascites, or pleural effusion); NTproBNP levels >1000 pg/mL or BNP >250 ng/mL on admission; Under treatment with furosemide and iSGLT2 according to European guidelines and indication of association of another diuretic due to residual congestion data defined by ADVOR SCORE>1.
Exclusion: Maintenance treatment with acetazolamide/ Treatment with acetazolamide in the month prior to inclusion in the study; Concurrent diagnosis of acute coronary syndrome; Type 1 diabetes mellitus; History of congenital heart disease requiring surgical correction; History of cardiac transplantation and/or ventricular assist device; Sulfonamide allergy, liver cirrhosis, renal lithiasis; GFR < 20 ml/min/m2 or renal replacement therapy/ultrafiltration at any time prior to the study; Serum potassium less than 3.5 mEq/L; Systolic blood pressure <90 mmHg or mean arterial pressure < 65 mmHg; Anticipated need for intravenous inotropes, vasopressors or nitroprusside during the study; Contraindication to ISGLT2; Anticipated exposure to nephrotoxic agents, such as iodinated contrast during admission; Pregnant or breastfeeding patients; Inability to adequately collect diuresis; Venous pH <7.30; Severe aortic stenosis or obstructive hypertrophic cardiomyopathy.